A Phase 2/3 Study to Assess the Safety and Efficacy of MultiStem Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease (COVID-19)

Status: Suspended

Phase of Trial: Phase II/III

Latest Information Update: 27 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Nov 2023 According to an Athersys media release, company received a second 1.5M dollars payment from Healios under the terms of the MOU associated with purchasing MultiStem bioreactor manufactured clinical doses to support Healios' Phase 3 ARDS trial.
11 Aug 2022 Status changed from recruiting to suspended, according to an Athersys media release.
11 Aug 2022 According to an Athersys media release, in order to focus resources on MASTERS-2, MACOVIA has been suspended until receive additional financing or establish a partnership to move forward with the next phase of the study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com